Table 2.

Summary of Recommendations for Use

RECOMMENDATIONS FOR USE
	PEOPLE WITH TYPE 2 DM	Grade
1	We recommend initiating SGLT-2 inhibition in people with chronic kidney disease and type 2 diabetes, irrespective of primary kidney disease,a for any of the following 4 clinical scenarios: a) eGFR of 20–45 mL/min/1.73m2 b) eGFR of > 45 mL/min/1.73m2 and a urinary albumin-to-creatinine ratio (uACR) of ≥ 25 mg/mmolb c) Symptomatic heart failure, irrespective of ejection fraction d) Established coronary disease	1A
2	We suggest initiating SGLT-2 inhibition to modify cardiovascular risk and slow rate of kidney function decline in people with an eGFR > 45–60 mL/min/1.73m2 and a uACR of < 25 mg/mmol, recognising effects on glycaemic control will be limited	2B
3	We suggest clinicians consider initiating SGLT-2 inhibition in people with an eGFR below 20 mL/min/1.73m2 to slow progression of kidney disease	2B
	PEOPLE WITHOUT DM
1	We recommend initiating SGLT-2 inhibition in people with chronic kidney disease, irrespective of primary kidney disease,a for any of the following clinical scenarios: (a) eGFR of ≥ 20 mL/min/1.73m2 and a urinary albumin-to-creatinine ratio (uACR) of ≥ 25 mg/mmolb (b) Symptomatic heart failure, irrespective of ejection fraction	1A
2	We recommend initiating SGLT-2 inhibition to slow rate of kidney function decline in people with an eGFR of 20–45 mL/min/1.73m2 and a uACR of < 25 mg/mmolb	1B
3	We suggest clinicians consider initiating SGLT-2 inhibition in people with an eGFR below 20 mL/min/1.73m2 to slow progression of kidney disease	2B

^aexcludes people with polycystic kidney disease, type 1 diabetes, or a kidney transplant

^burinary protein-to-creatinine ratio of 35 mg/mmol can be considered equivalent